Phase 3 Clinical Trial for Mocertatug Rezetecan in Endometrial Cancer Estimated to Begin

AI-generated NewsSnap summary based on source reporting.
Published: 2026-06-09
Category: health
Source: ClinicalTrials.gov
Original source

A Phase 3, randomized, open-label, multicenter study (BEHOLD-Endometrial01) investigating mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy is estimated to begin on June 9, 2026. The trial aims to evaluate the drug's efficacy, safety, and tolerability.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai